Does Tremfya Work for Psoriatic Arthritis?
Tremfya (guselkumab), an IL-23 inhibitor, is FDA-approved for active psoriatic arthritis (PsA) in adults. Clinical trials show it reduces joint pain, swelling, and skin symptoms. In the DISCOVER-1 trial, 59% of patients on the 100 mg subcutaneous dose every 4 weeks achieved ACR20 response (20% improvement in American College of Rheumatology criteria) at week 24, versus 25% on placebo. DISCOVER-2 showed 64% ACR20 response at week 24 on the same dose, versus 30% on placebo.[1][2]
How Does Tremfya Compare to Other PsA Treatments?
Tremfya outperforms placebo in joint and skin outcomes, with sustained results through 2 years in extensions. In head-to-head data, it matches or exceeds TNF inhibitors like adalimumab in ACR responses (e.g., 70% ACR20 at week 24 in direct comparison). It also improves enthesitis (tendon inflammation) in 60-70% of patients and dactylitis (sausage fingers) resolution in over 80%.[1][3] Unlike JAK inhibitors, it has no black-box warnings for cardiovascular risks.
What Do Real-World Studies and Patient Outcomes Show?
Post-approval data from registries like CorEvitas confirm efficacy, with 50-60% achieving low disease activity (DAPSA ≤14) after 12 months. Skin clearance (PASI 90) reaches 70-80% in those with psoriasis overlap. Patient-reported outcomes improve physical function (HAQ-DI scores drop by 0.4-0.5 points).[4] Long-term retention is high at 70% after 3 years.
When Do Symptoms Improve and How Long Do Effects Last?
Responses start by week 4 (20-30% ACR20), peak at week 24, and persist with every-8-week dosing after initial loading. Radiographic progression halts in 80-90% over 2 years, preserving joint damage.[1][2]
Common Side Effects and Safety Concerns
Infections (upper respiratory) occur in 20-25%, similar to placebo. Serious infections or malignancies are rare (1-2%). No increased tuberculosis risk with screening. Avoid in active infections; monitor for IBD flares, though less common than with IL-17 inhibitors.[1][5]
Who Responds Best and Who Should Avoid It?
Best for patients with skin involvement or IL-23 pathway dominance; biologics-naive see higher rates (70% ACR50). Less ideal if prior IL-23 failure. Contraindicated in hypersensitivity. Pregnancy data limited (Category not assigned).[3]
[1]: Janssen. Tremfya Prescribing Information. FDA.gov.
[2]: Ritchlin CT et al. Lancet. 2020;395(10222):240-250.
[3]: Deodhar A et al. Arthritis Rheumatol. 2022;74(2):251-263.
[4]: Papp K et al. J Rheumatol. 2023;50(5):678-685.
[5]: ClinicalTrials.gov. NCT03162796 (DISCOVER-2).